Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Sees Large Volume Increase – Time to Buy?

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) shares saw unusually-strong trading volume on Tuesday . 82,115 shares were traded during mid-day trading, a decline of 39% from the previous session’s volume of 135,097 shares.The stock last traded at $8.51 and had previously closed at $8.65.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on SGIOY shares. The Goldman Sachs Group raised Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a report on Monday, June 15th. Zacks Research raised shares of Shionogi & Co., Ltd. Unsponsored ADR from a “strong sell” rating to a “hold” rating in a research note on Monday, May 25th. One research analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy”.

Shionogi & Co., Ltd. Unsponsored ADR Stock Performance

The company has a debt-to-equity ratio of 0.01, a current ratio of 1.58 and a quick ratio of 1.46. The stock has a market cap of $14.28 billion, a price-to-earnings ratio of 10.49, a P/E/G ratio of 3.32 and a beta of 0.09. The stock’s 50-day moving average is $9.20 and its 200 day moving average is $9.90.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) last released its earnings results on Tuesday, May 12th. The company reported $0.18 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.15 by $0.03. The company had revenue of $881.71 million for the quarter, compared to analysts’ expectations of $895.52 million. Shionogi & Co., Ltd. Unsponsored ADR had a return on equity of 13.56% and a net margin of 41.08%. As a group, analysts predict that Shionogi & Co., Ltd. Unsponsored ADR will post 0.8 earnings per share for the current fiscal year.

Shionogi & Co., Ltd. Unsponsored ADR Company Profile

Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders.

The company’s product portfolio spans both established and innovative therapies.